Aktuellt
SENASTE
Redeye updates its view of IRLAB following the Q3 report and largely reiterate our previous view. We think that the next significant trigger is the outcome of the end-of-phase II meeting on Mesdopetam, which will determine the risk-reward profile for future development of the drug candidate in our view.
LÄS MER
